What is the current status of shock wave lithotripsy?

Neisius, Andreas

doi:10.1007/s00120-017-0470-9

Cited by 6 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…К ним относят количество, размер, локализацию, структурную плотность, химиче-ский состав, рентгенконтрастность и длитель-ность нахождения камня, длину шеек чашечек, чашечно-лоханочный угол, степень нарушения уродинамики и проходимость верхних мочевы-водящих путей, а также ожирение и сопутствую-щую инфекцию. Кроме того, при множественных и крупных камнях более 20 мм, располагающих-ся в нижней группе чашек, имеющих плотность выше +900 HU, эффективность ДЛТ снижается в два раза [7][8][9]. В результате возникает необ-ходимость в повторных сеансах литотрипсии, вспомогательных (стентирование мочеточника, нефростомия) и дополнительных хирургических пособиях (уретеролитотрипсия и уретеролитоэк-стракция), которые увеличивают койко-день и ма-териальные затраты на лечение [10].…”

Section: Introductionunclassified

Combined (citrate and herbal) drug uriklar in extracorporeal shock wave lithotripsy and metaphylaxis of urolithiasis

Shestaev

Юрьевич²,

Protoshchak

et al. 2018

Urolog vedom

View full text Add to dashboard Cite

The aim of the study was to study the clinical efficiency and safety of the drug uriklar in extracorporeal shock wave lithotripsy (ESWL) and early metaphylaxis of urolithiasis. Materials and methods. 45 patients were included in the prospective study. The patients were divided into two groups. The main group consisted of 25 patients, they received uriklar 1 capsule three times a day for one month before and three after ESWL. The control group included 20 patients who underwent ESWL only. Uriklar is combined drug with citrate and herbal components. Results. The total efficiency of ESWL was 92% in I group versus 75% in control group. Among the patients of the main group, the frequency of renal colic after ESWL was 24% (6 patients), while in the control group colic occurred in 9 patients (45%). The severity of pain syndrome was of 5.12 ± 2.1 in I group and of 7.48 ± 2.2 and in II group (p < 0.05). Uriklar in the first group of patients increased the pH of urine and the excretion of citrate significantly and decreased excretion of uric acid. After 3 months, the vast majority of patients (n = 24, 96%) of the main group underwent curing of the urinary tract, and daily diuresis remained at 2.3 ± 0.3 l/day. Conclusions. The uriklar taking increases the fragmentation of urinary stones and the elimination of the resulting fragments from the urinary tract, promotes the normalization of metabolic disorders, and effectively eliminates infectious-inflammatory complications of urolithiasis. It is also well-tolerated and has no side effects. (For citation: Shestaev AYu, Protoshchak VV, Paronnikov MV, Kiselev AO. Combined (citrate and herbal) drug uriklar in extracorporeal shock wave lithotripsy and metaphylaxis of urolithiasis. Urologicheskie vedomosti. 2018;8(1):19-25. doi: 10.17816/uroved8119-25).

show abstract